These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16417961)

  • 1. Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?
    van der Kwast TH
    Eur Urol; 2006 Feb; 49(2):209-11. PubMed ID: 16417961
    [No Abstract]   [Full Text] [Related]  

  • 2. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
    Chun FK; Briganti A; Lebeau T; Fradet V; Steuber T; Walz J; Schlomm T; Eichelberg C; Haese A; Erbersdobler A; McCormack M; Perrotte P; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2006 Feb; 49(2):273-8; discussion 278-9. PubMed ID: 16413103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis of prostate cancer].
    Strittmatter F
    MMW Fortschr Med; 2010 May; 152(19):40-2. PubMed ID: 20557001
    [No Abstract]   [Full Text] [Related]  

  • 4. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy.
    Chuang AY; Nielsen ME; Hernandez DJ; Walsh PC; Epstein JI
    J Urol; 2007 Oct; 178(4 Pt 1):1306-10. PubMed ID: 17698141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 6. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
    J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
    Shibata A
    Cancer; 1999 Mar; 85(5):1208-10. PubMed ID: 10091812
    [No Abstract]   [Full Text] [Related]  

  • 9. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression?].
    Wirth M
    Urologe A; 1998 Jul; 37(4):427-8. PubMed ID: 9738298
    [No Abstract]   [Full Text] [Related]  

  • 14. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 15. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
    Rampersaud EN; Sun L; Moul JW; Madden J; Freedland SJ
    J Urol; 2008 Aug; 180(2):571-6; discussion 576. PubMed ID: 18554662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
    J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is routine digital rectal examination required for the followup of prostate cancer?
    Warren KS; McFarlane JP
    J Urol; 2007 Jul; 178(1):115-9. PubMed ID: 17499293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
    Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
    Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
    BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.